Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02471846 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02471846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02471846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 28, 2015
Completion date
October 2, 2019
Enrollment
158 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor